The Center for Drug Evaluation (CDE) has given the green light for the review of a new indication submission for Jiangsu Hengrui Medicine Co., Ltd’s (SHA: 600276) ivarmacitinib, as per the latest update on the CDE’s website. The potential new indication is speculated to be adult alopecia areata, aligning with the clinical trials conducted for this condition.
Ivarmacitinib, a JAK1 inhibitor developed domestically in China, is already under regulatory review for marketing approval to treat ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. This latest development marks another step forward for the drug as it aims to expand its therapeutic applications.- Flcube.com
